Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva, an anti-CD20 monoclonal antibody designed for enhanced B cell depletion Genentech, a
Augmented Reality Glasses Purpose-Built for the Medical Technology Industry MDIC Medical XR Summit – Snke OS GmbH has announced the unveiling of SnkeXR, the first medical grade, open
Sophie Lamle brings over 20 years of experience in the pharmaceutical industry, leading innovation, clinical development, and strategic transformation. LEO Pharma, a leader in medical
Dylan Hushka appointed Chief Executive Officer SK Capital Partners, a New York-based private investment firm focused on the specialty materials, ingredients, and life sciences sectors,
Industry leaders join forces to bring advanced AI capabilities to dental technology platforms — redefining patient care, clinical efficiency, and practice performance worldwide Henry Schein
Findings Reinforce QDENGA’s Long-Term Safety Profile and Two-Dose Vaccination Schedule Takeda announced the completion of the 7-year pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study
Imagine walking into a hospital floor in 2026 and seeing an AI assistant reviewing imaging scans, smart wearable rings relaying real-time health data, and remote
Acquisition Expands UPS Healthcare’s Quality Focused, Patient Driven Cold Chain and Pharma Capabilities across North America and around the world UPS announced that it has
Circle Pharma, Inc., a clinical-stage biopharmaceutical company developing next-generation macrocycle therapeutics to target cancer, announced the appointment of Rob Lauzen as its new Chief Financial
Vistagen, a late-stage clinical biopharmaceutical company focused on neuroscience and developing intranasal therapies called pherines, announced that the final patient has completed the randomized, double-blind,
Royal Philips, a global leader in health technology, has announced its support for the Forever Promise Project, an initiative led by the Monuments Men and
Arctic Therapeutics, a clinical-stage biopharmaceutical company based in Iceland, has announced regulatory clearance from the European Medicines Agency to begin a Phase IIa clinical trial
